BJ Rimel, MD, Discusses Biggest Takeaways from 2021 SGO Annual Meeting

Video

Rimel, of the Cedars-Sinai Medical Center, focused her attention on the main takeaways to come out from the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

BJ Rimel, MD, of the Cedars-Sinai Medical Center spoke to CancerNetwork® regarding her biggest takeaways when it comes to the data presented at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Transcription:

The biggest takeaway for the annual meeting for me is the excitement around seeing the perspectives of clinical trials, innovations in office care, [and] innovations in how we approach getting data from patients or about patients to serve them better. I really thought that was an exciting part of the meeting and I’m looking forward to seeing more of it.

Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Related Content